AI in Drug Discovery Market: Global Growth, Trends, Opportunities, and Future Outlook

The AI in Drug Discovery Market is experiencing rapid expansion as pharmaceutical and biotechnology companies increasingly adopt artificial intelligence to accelerate research, improve candidate selection, and reduce drug development costs. According to Market Research Future, the market was valued at USD 2.81 billion in 2025 and is projected to reach USD 23.95 billion by 2035, registering a CAGR of 23.9% during 2026–2035.

AI technologies are being integrated across target identification, lead optimization, drug repurposing, preclinical testing, and clinical trial processes. Machine learning remains a major technology because it can analyze large biological and chemical datasets and identify patterns that may be difficult to detect through conventional approaches.

The growing volume of genomic, proteomic, clinical, and molecular data is another important market driver. AI platforms can process these datasets to support target discovery, molecular design, and predictive modeling. Increasing pharmaceutical investment in AI partnerships and computational research is further strengthening adoption.

North America currently leads the market, supported by its strong biotechnology ecosystem, research funding, and concentration of pharmaceutical companies. Asia-Pacific is expected to demonstrate rapid growth as countries such as China and India expand their AI and pharmaceutical capabilities.

Overall, advances in machine learning, deep learning, generative AI, automation, and biological foundation models are expected to transform drug discovery workflows and create significant opportunities for technology providers and pharmaceutical organizations.

Read More
Lukoon https://lukoon.com